Advanced Cell Technology

Marlborough biotech firm Advanced Cell Technology said it has picked up $30 million in capital through a common stock purchase agreement with a Chicago-based investment firm. The deal, with Lincoln Park Capital Fund, gives Advanced Cell (ACT) another funding option to grow its business “without creating complications in our capital structure” as the company pushes for long-term, “fundamental-based institutional capital.” interim president, CEO and COO Ted Myles said in a statement.

Advanced Cell Technology (ACT), a Marlborough-based biotechnology firm that is developing stem cell treatments for diseases causing blindness, has hired an industry veteran as its new president and CEO.

On the surface, Marlborough biotechnology company Advanced Cell Technology appears to be on a rocky road, with...

Losses mounted and revenue declined in 2013 for Advanced Cell Technology (ACT) of Marlborough, which announced its financial results for fiscal 2013 Tuesday.

Marlborough-based Advanced Cell Technology said a new stem cell development method might allow for treatment for additional types of inflammatory and autoimmune conditions.

Marlborough-based Advanced Cell Technology announced Monday that it will restate financial results between 2009 and 2013 because it misapplied accounting guidance related to stock warrants issued in September 2005.

Marlborough-based Advanced Cell Technology announced today that CEO Gary Rabin is leaving his position, and his seat on the company's Board of Directors, effective immediately.

Advanced Cell Technology of Marlborough agreed last week to pay $4.1 million over the next 18 months to settle claims by the U.S. Securities and Exchange Commission that the biotechnology firm sold billions of shares of unregistered penny stocks.

Advanced Cell Technology of Marlborough reported another quarterly loss as it continued testing for a vision-treatment drug and applied for federal approval of another drug that could potentially treat both humans and animals.

As clinical trials continue for its macular degeneration treatment, Marlborough-based Advanced Cell Technology reported falling revenue and greater losses in the second quarter.